RIPK1: A rising star in inflammatory and neoplastic skin diseases. Issue 3 (September 2020)

• Record Type: Journal Article
• Authors: Jin, Liping; Liu, Panpan; Yin, Mingzhu; Zhang, Mi; Kuang, Yehong; Zhu, Wu
• Is Part Of: Journal of dermatological science. Volume 99:Issue 3(2020)
• Page Start: 146
• Page End: 151
• Publication Date: 2020-09
• Subjects: RIPK1 -- Inflammation -- Psoriasis -- Systemic lupus erythematosus -- Melanoma -- Skin disease; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2020.06.001
• Languages: English
• ISSNs: 0923-1811

Abstract

Highlights: RIPK1 plays an important role in cell death, especially necroptosis, associated with inflammation and tumor. Activation of RIPK1 is correlated with many skin diseases, including melanoma, psoriasis, systemic lupus erythematosus. Inhibitors of RIPK1 may be a new strategy for skin diseases. Abstract: Skin diseases bring great psychological and physical impacts on patients, however, a considerable number of skin diseases still lack effective treatments, such as psoriasis, systemic lupus erythematosus, melanoma and so on. Receptor-interacting serine threonine kinase 1 (RIPK1) plays an important role in cell death, especially necroptosis, associated with inflammation and tumor. As many molecules modulate the ubiquitination of RIPK1, disruption of this checkpoint can lead to skin diseases, which can be ameliorated by RIPK1 inhibitors. This review will focus on the molecular mechanism of RIPK1 activation in inflammation as well as the current knowledges on the contribution of RIPK1 in skin diseases.